{"parse":{"title":"Postmarketing surveillance","pageid":7020455,"revid":859015106,"text":{"*":"<div class=\"mw-parser-output\"><p><b>Postmarketing surveillance</b> (<b>PMS</b>) (also <i><b>post market surveillance</b></i>) is the practice of monitoring the safety of a <a href=\"/wiki/Pharmaceutical_drug\" class=\"mw-redirect\" title=\"Pharmaceutical drug\">pharmaceutical drug</a> or <a href=\"/wiki/Medical_device\" title=\"Medical device\">medical device</a> after it has been released on the market and is an important part of the science of <a href=\"/wiki/Pharmacovigilance\" title=\"Pharmacovigilance\">pharmacovigilance</a>. Since drugs and medical devices are approved on the basis of <a href=\"/wiki/Clinical_trial\" title=\"Clinical trial\">clinical trials</a>, which involve relatively small numbers of people who have been selected for this purpose \u2013 meaning that they normally do not have other medical conditions which may exist in the general population \u2013 postmarketing <a href=\"/wiki/Surveillance\" title=\"Surveillance\">surveillance</a> can further refine, or confirm or deny, the safety of a drug or device after it is used in the general population by large numbers of people who have a wide variety of medical conditions.<sup id=\"cite_ref-:0_1-0\" class=\"reference\"><a href=\"#cite_note-:0-1\">&#91;1&#93;</a></sup>\n</p><p>Postmarketing surveillance uses a number of approaches to monitor drug and device safety, including spontaneous reporting databases, prescription event monitoring, <a href=\"/wiki/Electronic_health_record\" title=\"Electronic health record\">electronic health records</a>, <a href=\"/wiki/Disease_registry\" title=\"Disease registry\">patient registries</a>, and <a href=\"/wiki/Record_linkage\" title=\"Record linkage\">record linkage</a> between health databases.<sup id=\"cite_ref-:0_1-1\" class=\"reference\"><a href=\"#cite_note-:0-1\">&#91;1&#93;</a></sup> These data are reviewed to highlight potential safety concerns in a process known as <a href=\"/wiki/Data_mining\" title=\"Data mining\">data mining</a>.\n</p>\n<div id=\"toc\" class=\"toc\"><input type=\"checkbox\" role=\"button\" id=\"toctogglecheckbox\" class=\"toctogglecheckbox\" style=\"display:none\" /><div class=\"toctitle\" lang=\"en\" dir=\"ltr\"><h2>Contents</h2><span class=\"toctogglespan\"><label class=\"toctogglelabel\" for=\"toctogglecheckbox\"></label></span></div>\n<ul>\n<li class=\"toclevel-1 tocsection-1\"><a href=\"#National_implementation\"><span class=\"tocnumber\">1</span> <span class=\"toctext\">National implementation</span></a>\n<ul>\n<li class=\"toclevel-2 tocsection-2\"><a href=\"#Canada\"><span class=\"tocnumber\">1.1</span> <span class=\"toctext\">Canada</span></a></li>\n<li class=\"toclevel-2 tocsection-3\"><a href=\"#European_Union\"><span class=\"tocnumber\">1.2</span> <span class=\"toctext\">European Union</span></a></li>\n<li class=\"toclevel-2 tocsection-4\"><a href=\"#United_Kingdom\"><span class=\"tocnumber\">1.3</span> <span class=\"toctext\">United Kingdom</span></a></li>\n<li class=\"toclevel-2 tocsection-5\"><a href=\"#United_States\"><span class=\"tocnumber\">1.4</span> <span class=\"toctext\">United States</span></a></li>\n</ul>\n</li>\n<li class=\"toclevel-1 tocsection-6\"><a href=\"#See_also\"><span class=\"tocnumber\">2</span> <span class=\"toctext\">See also</span></a></li>\n<li class=\"toclevel-1 tocsection-7\"><a href=\"#References\"><span class=\"tocnumber\">3</span> <span class=\"toctext\">References</span></a></li>\n</ul>\n</div>\n\n<h2><span class=\"mw-headline\" id=\"National_implementation\">National implementation</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Postmarketing_surveillance&amp;action=edit&amp;section=1\" title=\"Edit section: National implementation\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<h3><span class=\"mw-headline\" id=\"Canada\">Canada</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Postmarketing_surveillance&amp;action=edit&amp;section=2\" title=\"Edit section: Canada\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p><a href=\"/wiki/Health_Canada\" title=\"Health Canada\">Health Canada</a> is the regulatory body which approves drugs, and it has a division called \"Marketed Health Products Directorate\" (MHPD) which coordinates Canadian postmarketing surveillance.<sup id=\"cite_ref-2\" class=\"reference\"><a href=\"#cite_note-2\">&#91;2&#93;</a></sup>\n</p>\n<h3><span class=\"mw-headline\" id=\"European_Union\">European Union</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Postmarketing_surveillance&amp;action=edit&amp;section=3\" title=\"Edit section: European Union\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The guidance document \"MEDDEV 2.12-1 rev 8\" offers a comprehensive guidance on best practice for <i>medical device post-market surveillance</i> (materiovigilance). A manufacturer of medical devices is required to report incidents (serious adverse events) to the national competent authority of the member state the company resides in.\n</p>\n<h3><span class=\"mw-headline\" id=\"United_Kingdom\">United Kingdom</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Postmarketing_surveillance&amp;action=edit&amp;section=4\" title=\"Edit section: United Kingdom\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>The <a href=\"/wiki/Medicines_and_Healthcare_Products_Regulatory_Agency\" class=\"mw-redirect\" title=\"Medicines and Healthcare Products Regulatory Agency\">Medicines and Healthcare Products Regulatory Agency</a> (MHRA) and the <a href=\"/wiki/Commission_on_Human_Medicines\" title=\"Commission on Human Medicines\">Commission on Human Medicines</a> (CHM) jointly operate the <a href=\"/wiki/Yellow_Card_Scheme\" title=\"Yellow Card Scheme\">Yellow Card Scheme</a>, which was one of the first examples of a pharmacovigilance scheme, aimed at mitigating <a href=\"/wiki/Adverse_drug_reaction\" title=\"Adverse drug reaction\">adverse drug reactions</a> (ADRs).\n</p>\n<h3><span class=\"mw-headline\" id=\"United_States\">United States</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Postmarketing_surveillance&amp;action=edit&amp;section=5\" title=\"Edit section: United States\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h3>\n<p>Postmarketing surveillance is overseen by the <a href=\"/wiki/Food_and_Drug_Administration_(United_States)\" class=\"mw-redirect\" title=\"Food and Drug Administration (United States)\">Food and Drug Administration</a> (FDA), which operates a system of passive surveillance called <a href=\"/wiki/MedWatch\" title=\"MedWatch\">MedWatch</a>, to which doctors or the general public can voluntarily report adverse reactions to drugs and medical devices.<sup id=\"cite_ref-3\" class=\"reference\"><a href=\"#cite_note-3\">&#91;3&#93;</a></sup> The FDA also conducts active surveillance of certain regulated products. For example, the FDA may monitor safety and effectiveness of medical devices through either a Post-Approval Study<sup id=\"cite_ref-4\" class=\"reference\"><a href=\"#cite_note-4\">&#91;4&#93;</a></sup> or through a 522 Postmarket Surveillance Study.<sup id=\"cite_ref-5\" class=\"reference\"><a href=\"#cite_note-5\">&#91;5&#93;</a></sup>\n</p>\n<h2><span class=\"mw-headline\" id=\"See_also\">See also</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Postmarketing_surveillance&amp;action=edit&amp;section=6\" title=\"Edit section: See also\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<ul><li><a href=\"/wiki/Medical_device_reporting\" title=\"Medical device reporting\">Medical device reporting</a></li>\n<li><a href=\"/wiki/List_of_withdrawn_drugs\" title=\"List of withdrawn drugs\">List of withdrawn drugs</a></li></ul>\n<h2><span class=\"mw-headline\" id=\"References\">References</span><span class=\"mw-editsection\"><span class=\"mw-editsection-bracket\">[</span><a href=\"/w/index.php?title=Postmarketing_surveillance&amp;action=edit&amp;section=7\" title=\"Edit section: References\">edit</a><span class=\"mw-editsection-bracket\">]</span></span></h2>\n<div class=\"mw-references-wrap\"><ol class=\"references\">\n<li id=\"cite_note-:0-1\"><span class=\"mw-cite-backlink\">^ <a href=\"#cite_ref-:0_1-0\"><sup><i><b>a</b></i></sup></a> <a href=\"#cite_ref-:0_1-1\"><sup><i><b>b</b></i></sup></a></span> <span class=\"reference-text\"><cite class=\"citation journal\">McNeil JJ, Piccenna L, Ronaldson K,  et al. (2010). <a rel=\"nofollow\" class=\"external text\" href=\"http://adisonline.com/pharmaceuticalmedicine/Fulltext/2010/24050/The_Value_of_Patient_Centred_Registries_in_Phase.2.aspx\">\"The Value of Patient-Centred Registries in Phase IV Drug Surveillance\"</a>. <i>Pharm Med</i>. <b>24</b> (5): 281\u2013288. <a href=\"/wiki/Digital_object_identifier\" title=\"Digital object identifier\">doi</a>:<a rel=\"nofollow\" class=\"external text\" href=\"//doi.org/10.1007/bf03256826\">10.1007/bf03256826</a>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pharm+Med&amp;rft.atitle=The+Value+of+Patient-Centred+Registries+in+Phase+IV+Drug+Surveillance&amp;rft.volume=24&amp;rft.issue=5&amp;rft.pages=281-288&amp;rft.date=2010&amp;rft_id=info%3Adoi%2F10.1007%2Fbf03256826&amp;rft.aulast=McNeil&amp;rft.aufirst=JJ&amp;rft.au=Piccenna%2C+L&amp;rft.au=Ronaldson%2C+K&amp;rft_id=http%3A%2F%2Fadisonline.com%2Fpharmaceuticalmedicine%2FFulltext%2F2010%2F24050%2FThe_Value_of_Patient_Centred_Registries_in_Phase.2.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APostmarketing+surveillance\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-2\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-2\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.hc-sc.gc.ca/hcs-sss/pubs/pharma/2005-pharma-surveill-can/ref-can_3_4-eng.php\">\"Post-marketing Pharmacosurveillance in Canada\"</a>. Health Canada. 2005<span class=\"reference-accessdate\">. Retrieved <span class=\"nowrap\">2010-07-27</span></span>.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Post-marketing+Pharmacosurveillance+in+Canada&amp;rft.pub=Health+Canada&amp;rft.date=2005&amp;rft_id=http%3A%2F%2Fwww.hc-sc.gc.ca%2Fhcs-sss%2Fpubs%2Fpharma%2F2005-pharma-surveill-can%2Fref-can_3_4-eng.php&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APostmarketing+surveillance\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-3\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-3\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.fda.gov/cder/regulatory/applications/Postmarketing/surveillancepost.htm\">\"Post-marketing Surveillance\"</a>. U.S. FDA/CDER. 2004.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Post-marketing+Surveillance&amp;rft.pub=U.S.+FDA%2FCDER&amp;rft.date=2004&amp;rft_id=http%3A%2F%2Fwww.fda.gov%2Fcder%2Fregulatory%2Fapplications%2FPostmarketing%2Fsurveillancepost.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APostmarketing+surveillance\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-4\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-4\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma_pas.cfm\">\"Post-Approval Studies\"</a>. U.S. FDA/CDRH. 2014.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Post-Approval+Studies&amp;rft.pub=U.S.+FDA%2FCDRH&amp;rft.date=2014&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcdrh%2Fcfdocs%2Fcfpma%2Fpma_pas.cfm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APostmarketing+surveillance\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n<li id=\"cite_note-5\"><span class=\"mw-cite-backlink\"><b><a href=\"#cite_ref-5\">^</a></b></span> <span class=\"reference-text\"><cite class=\"citation web\"><a rel=\"nofollow\" class=\"external text\" href=\"http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pss.cfm\">\"522 Postmarket Surveillance Studies\"</a>. U.S. FDA/CDRH. 2014.</cite><span title=\"ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=522+Postmarket+Surveillance+Studies&amp;rft.pub=U.S.+FDA%2FCDRH&amp;rft.date=2014&amp;rft_id=http%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcdrh%2Fcfdocs%2FcfPMA%2Fpss.cfm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3APostmarketing+surveillance\" class=\"Z3988\"><span style=\"display:none;\">&#160;</span></span></span>\n</li>\n</ol></div>\n\n<!-- \nNewPP limit report\nParsed by mw1327\nCached time: 20180911043526\nCache expiry: 1900800\nDynamic content: false\nCPU time usage: 0.076 seconds\nReal time usage: 0.096 seconds\nPreprocessor visited node count: 198/1000000\nPreprocessor generated node count: 0/1500000\nPost\u2010expand include size: 6918/2097152 bytes\nTemplate argument size: 0/2097152 bytes\nHighest expansion depth: 3/40\nExpensive parser function count: 0/500\nUnstrip recursion depth: 0/20\nUnstrip post\u2010expand size: 5264/5000000 bytes\nNumber of Wikibase entities loaded: 0/400\nLua time usage: 0.035/10.000 seconds\nLua memory usage: 2.17 MB/50 MB\n-->\n<!--\nTransclusion expansion time report (%,ms,calls,template)\n100.00%   70.978      1 -total\n 79.13%   56.168      1 Template:Cite_journal\n 20.44%   14.510      4 Template:Cite_web\n-->\n\n<!-- Saved in parser cache with key enwiki:pcache:idhash:7020455-0!canonical and timestamp 20180911043526 and revision id 859015106\n -->\n</div>"},"langlinks":[{"lang":"es","url":"https://es.wikipedia.org/wiki/Vigilancia_posterior_a_la_comercializaci%C3%B3n","langname":"Spanish","autonym":"espa\u00f1ol","*":"Vigilancia posterior a la comercializaci\u00f3n"}],"categories":[{"sortkey":"","*":"Clinical_research"},{"sortkey":"","*":"Clinical_trials"},{"sortkey":"","*":"Pharmaceuticals_policy"},{"sortkey":"","*":"Regulation_of_medical_devices"}],"links":[{"ns":0,"exists":"","*":"Adverse drug reaction"},{"ns":0,"exists":"","*":"Clinical trial"},{"ns":0,"exists":"","*":"Commission on Human Medicines"},{"ns":0,"exists":"","*":"Data mining"},{"ns":0,"exists":"","*":"Digital object identifier"},{"ns":0,"exists":"","*":"Disease registry"},{"ns":0,"exists":"","*":"Electronic health record"},{"ns":0,"exists":"","*":"Food and Drug Administration (United States)"},{"ns":0,"exists":"","*":"Health Canada"},{"ns":0,"exists":"","*":"List of withdrawn drugs"},{"ns":0,"exists":"","*":"MedWatch"},{"ns":0,"exists":"","*":"Medical device"},{"ns":0,"exists":"","*":"Medical device reporting"},{"ns":0,"exists":"","*":"Medicines and Healthcare Products Regulatory Agency"},{"ns":0,"exists":"","*":"Pharmaceutical drug"},{"ns":0,"exists":"","*":"Pharmacovigilance"},{"ns":0,"exists":"","*":"Record linkage"},{"ns":0,"exists":"","*":"Surveillance"},{"ns":0,"exists":"","*":"Yellow Card Scheme"}],"templates":[{"ns":10,"exists":"","*":"Template:Cite journal"},{"ns":10,"exists":"","*":"Template:Cite web"},{"ns":828,"exists":"","*":"Module:Citation/CS1"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Configuration"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Whitelist"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Utilities"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Date validation"},{"ns":828,"exists":"","*":"Module:Citation/CS1/Identifiers"},{"ns":828,"exists":"","*":"Module:Citation/CS1/COinS"}],"images":[],"externallinks":["http://adisonline.com/pharmaceuticalmedicine/Fulltext/2010/24050/The_Value_of_Patient_Centred_Registries_in_Phase.2.aspx","//doi.org/10.1007/bf03256826","http://www.hc-sc.gc.ca/hcs-sss/pubs/pharma/2005-pharma-surveill-can/ref-can_3_4-eng.php","http://www.fda.gov/cder/regulatory/applications/Postmarketing/surveillancepost.htm","http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma_pas.cfm","http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMA/pss.cfm"],"sections":[{"toclevel":1,"level":"2","line":"National implementation","number":"1","index":"1","fromtitle":"Postmarketing_surveillance","byteoffset":1574,"anchor":"National_implementation"},{"toclevel":2,"level":"3","line":"Canada","number":"1.1","index":"2","fromtitle":"Postmarketing_surveillance","byteoffset":1602,"anchor":"Canada"},{"toclevel":2,"level":"3","line":"European Union","number":"1.2","index":"3","fromtitle":"Postmarketing_surveillance","byteoffset":2033,"anchor":"European_Union"},{"toclevel":2,"level":"3","line":"United Kingdom","number":"1.3","index":"4","fromtitle":"Postmarketing_surveillance","byteoffset":2387,"anchor":"United_Kingdom"},{"toclevel":2,"level":"3","line":"United States","number":"1.4","index":"5","fromtitle":"Postmarketing_surveillance","byteoffset":2691,"anchor":"United_States"},{"toclevel":1,"level":"2","line":"See also","number":"2","index":"6","fromtitle":"Postmarketing_surveillance","byteoffset":3760,"anchor":"See_also"},{"toclevel":1,"level":"2","line":"References","number":"3","index":"7","fromtitle":"Postmarketing_surveillance","byteoffset":3836,"anchor":"References"}],"parsewarnings":[],"displaytitle":"Postmarketing surveillance","iwlinks":[],"properties":[{"name":"wikibase_item","*":"Q7234359"}]}}